erythromycin has been researched along with Cardiac Arrest, Sudden in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 9 (81.82) | 29.6817 |
2010's | 1 (9.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Li, C; Li, X; Liu, G; Wang, M; Wang, Z; Zhou, L | 1 |
Juurlink, DN; Liu, BA | 1 |
Hall, K; Meredith, S; Murray, KT; Narasimhulu, SS; Ray, WA; Stein, CM | 1 |
Kaplan, EL | 1 |
Amory, DW; Amory, JK | 1 |
Winston, AP | 1 |
de Leon-Casasola, OA; Harris, JD | 1 |
Schoenholtz, JC | 1 |
Carlson, W; Choo, PW; Faich, GA; Greineder, D; Hanrahan, JP; Platt, R | 1 |
11 other study(ies) available for erythromycin and Cardiac Arrest, Sudden
Article | Year |
---|---|
Macrolides use and the risk of sudden cardiac death.
Topics: Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; Clarithromycin; Coronary Artery Disease; Coronary Disease; Death, Sudden, Cardiac; Erythromycin; Humans; Macrolides; Plaque, Atherosclerotic; Risk Factors; Torsades de Pointes | 2016 |
Drugs and the QT interval - caveat doctor.
Topics: Anti-Bacterial Agents; Cytochrome P-450 Enzyme Inhibitors; Death, Sudden, Cardiac; Drug Interactions; Electrocardiography; Erythromycin; Humans; Torsades de Pointes | 2004 |
Oral erythromycin and the risk of sudden death from cardiac causes.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Confounding Factors, Epidemiologic; Cytochrome P-450 CYP3A; Death, Sudden, Cardiac; Diltiazem; Drug Interactions; Erythromycin; Female; Humans; Male; Middle Aged; Multivariate Analysis; Nitroimidazoles; Oxidoreductases, N-Demethylating; Risk; Troleandomycin; Verapamil | 2004 |
Oral erythromycin and the risk of sudden death.
Topics: Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Death, Sudden, Cardiac; Drug Interactions; Erythromycin; HIV Infections; Humans; Macrolides; Oxidoreductases, N-Demethylating | 2005 |
Oral erythromycin and the risk of sudden death.
Topics: Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Beverages; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Death, Sudden, Cardiac; Drug Interactions; Erythromycin; Humans; Oxidoreductases, N-Demethylating | 2005 |
Oral erythromycin and the risk of sudden death.
Topics: Anorexia Nervosa; Anti-Bacterial Agents; Cytochrome P-450 Enzyme Inhibitors; Death, Sudden, Cardiac; Drug Interactions; Electrocardiography; Erythromycin; Humans | 2005 |
Oral erythromycin and the risk of sudden death.
Topics: Anti-Bacterial Agents; Cytochrome P-450 Enzyme Inhibitors; Death, Sudden, Cardiac; Drug Interactions; Electrocardiography; Erythromycin; Humans; Methadone; Narcotics; Torsades de Pointes | 2005 |
Oral erythromycin and the risk of sudden death.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Cytochrome P-450 Enzyme Inhibitors; Death, Sudden, Cardiac; Drug Interactions; Electrocardiography; Erythromycin; Haloperidol; Humans; Thioridazine | 2005 |
Combining erythromycin with other drugs may lead to sudden death.
Topics: Anti-Bacterial Agents; Arrhythmias, Cardiac; Aryl Hydrocarbon Hydroxylases; Contraindications; Cytochrome P-450 CYP3A; Death, Sudden, Cardiac; Drug Interactions; Drug Therapy, Combination; Erythromycin; Humans; Oxidoreductases, N-Demethylating | 2005 |
Antibiotic increases risk of sudden death.
Topics: Anti-Bacterial Agents; Death, Sudden, Cardiac; Drug Interactions; Drug Therapy, Combination; Erythromycin; Humans; Torsades de Pointes | 2005 |
Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization.
Topics: Administration, Oral; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Boston; Cohort Studies; Death, Sudden, Cardiac; Drug Interactions; Electrocardiography; Erythromycin; Female; Health Maintenance Organizations; Heart Rate; Histamine H1 Antagonists; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Syncope; Terfenadine; Treatment Outcome; Ventricular Dysfunction | 1995 |